LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

Gossamer Bio Inc

Geschlossen

BrancheGesundheitswesen

1.18 2.61

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.11

Max

1.2

Schlüsselkennzahlen

By Trading Economics

Einkommen

-3.6M

-37M

Verkäufe

510K

9.9M

EPS

-0.16

Gewinnspanne

-370.492

Angestellte

144

EBITDA

-5.2M

-37M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+660.87% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

8. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2.3M

248M

Vorheriger Eröffnungskurs

-1.43

Vorheriger Schlusskurs

1.18

Nachrichtenstimmung

By Acuity

50%

50%

174 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Gossamer Bio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Mai 2025, 23:48 UTC

Heiße Aktien

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22. Mai 2025, 23:07 UTC

Top News

Fortescue Energy CEO to Resign in Executive Overhaul

22. Mai 2025, 23:03 UTC

Wichtige Markttreiber

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22. Mai 2025, 23:59 UTC

Market Talk

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22. Mai 2025, 23:45 UTC

Market Talk

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22. Mai 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

22. Mai 2025, 23:23 UTC

Market Talk

Global Energy Roundup: Market Talk

22. Mai 2025, 23:23 UTC

Market Talk

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22. Mai 2025, 23:12 UTC

Top News

Supreme Court Lets Trump Fire Agency Officials, but Moves to Protect Fed -- WSJ

22. Mai 2025, 21:54 UTC

Top News

Global Finance Officials Gloss Over Trade Tensions At G-7 Summit -- WSJ

22. Mai 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22. Mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. Mai 2025, 20:46 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22. Mai 2025, 20:39 UTC

Ergebnisse

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22. Mai 2025, 20:36 UTC

Top News

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22. Mai 2025, 20:36 UTC

Top News
Ergebnisse

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22. Mai 2025, 20:32 UTC

Top News
Ergebnisse

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22. Mai 2025, 20:27 UTC

Top News

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22. Mai 2025, 20:20 UTC

Top News

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22. Mai 2025, 20:17 UTC

Top News

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22. Mai 2025, 20:16 UTC

Ergebnisse

Intchains Group 1Q Rev $18.2M >ICG

22. Mai 2025, 20:15 UTC

Top News

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22. Mai 2025, 20:08 UTC

Top News
Ergebnisse

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22. Mai 2025, 20:05 UTC

Top News

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22. Mai 2025, 20:04 UTC

Ergebnisse

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22. Mai 2025, 20:04 UTC

Ergebnisse

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22. Mai 2025, 20:01 UTC

Ergebnisse

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22. Mai 2025, 20:01 UTC

Ergebnisse

Workday 1Q Net $68M >WDAY

22. Mai 2025, 20:01 UTC

Ergebnisse

Workday 1Q EPS 25c >WDAY

22. Mai 2025, 20:01 UTC

Ergebnisse

Workday 1Q Adj EPS $2.23 >WDAY

Peer-Vergleich

Kursveränderung

Gossamer Bio Inc Prognose

Kursziel

By TipRanks

660.87% Vorteil

12-Monats-Prognose

Durchschnitt 8.75 USD  660.87%

Hoch 15 USD

Tief 4 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gossamer Bio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

5

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

1.06 / 1.23Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

174 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.